IL269182B2 - Methods of treating and/or preventing actinic keratosis - Google Patents

Methods of treating and/or preventing actinic keratosis

Info

Publication number
IL269182B2
IL269182B2 IL269182A IL26918219A IL269182B2 IL 269182 B2 IL269182 B2 IL 269182B2 IL 269182 A IL269182 A IL 269182A IL 26918219 A IL26918219 A IL 26918219A IL 269182 B2 IL269182 B2 IL 269182B2
Authority
IL
Israel
Prior art keywords
days
administered
compound
subject
affected area
Prior art date
Application number
IL269182A
Other languages
English (en)
Hebrew (he)
Other versions
IL269182B1 (en
IL269182A (en
Original Assignee
Athenex Inc
Antx Spv Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=63446658&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL269182(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Athenex Inc, Antx Spv Llc filed Critical Athenex Inc
Publication of IL269182A publication Critical patent/IL269182A/en
Publication of IL269182B1 publication Critical patent/IL269182B1/en
Publication of IL269182B2 publication Critical patent/IL269182B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL269182A 2017-03-10 2018-03-12 Methods of treating and/or preventing actinic keratosis IL269182B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762469889P 2017-03-10 2017-03-10
PCT/US2018/021929 WO2018165647A1 (en) 2017-03-10 2018-03-12 Methods of treating and/or preventing actinic keratosis

Publications (3)

Publication Number Publication Date
IL269182A IL269182A (en) 2019-11-28
IL269182B1 IL269182B1 (en) 2023-07-01
IL269182B2 true IL269182B2 (en) 2023-11-01

Family

ID=63446658

Family Applications (1)

Application Number Title Priority Date Filing Date
IL269182A IL269182B2 (en) 2017-03-10 2018-03-12 Methods of treating and/or preventing actinic keratosis

Country Status (13)

Country Link
US (3) US10617693B2 (enExample)
EP (2) EP4659740A2 (enExample)
JP (3) JP7502863B2 (enExample)
KR (2) KR20190141661A (enExample)
CN (1) CN110891575A (enExample)
AU (2) AU2018231144B2 (enExample)
BR (1) BR112019018687A2 (enExample)
CA (1) CA3055938A1 (enExample)
IL (1) IL269182B2 (enExample)
MX (2) MX387658B (enExample)
TW (1) TWI841523B (enExample)
WO (1) WO2018165647A1 (enExample)
ZA (1) ZA202100106B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7968574B2 (en) * 2004-12-28 2011-06-28 Kinex Pharmaceuticals, Llc Biaryl compositions and methods for modulating a kinase cascade
TWI841523B (zh) * 2017-03-10 2024-05-11 美商Ａｔｎｘ特殊目的實體公司 治療及／或預防光化性角化症之方法
SG11202001868RA (en) 2017-09-07 2020-03-30 Athenex Hk Innovative Ltd Solid forms of 2-(5-(4-(2-morpholinoethoxy)phenyl)pyridin-2-yl)-n-benzylacetamide
US11752156B2 (en) * 2018-03-07 2023-09-12 Athenex HK Innovative Limited Compositions and methods for treating hyperproliferative skin disorders
WO2019188918A1 (ja) * 2018-03-28 2019-10-03 テルモ株式会社 医療デバイスおよび処置用法
US20220305021A1 (en) * 2019-06-05 2022-09-29 Athenex, Inc. Methods of treating and/or preventing psoriasis
EP4263833A1 (en) * 2021-01-21 2023-10-25 Sirnaomics, Inc. Compositions and methods for treatment of skin cancers
WO2025077886A1 (zh) * 2023-10-13 2025-04-17 恩康药业科技（广州）有限公司 治疗和/或预防日光性角化病的化合物及方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103274961B (zh) 2004-12-28 2016-05-18 阿西纳斯公司 治疗细胞增殖紊乱的化合物和方法
US7968574B2 (en) 2004-12-28 2011-06-28 Kinex Pharmaceuticals, Llc Biaryl compositions and methods for modulating a kinase cascade
CA2656564C (en) 2006-06-29 2015-06-16 Kinex Pharmaceuticals, Llc Biaryl compositions and methods for modulating a kinase cascade
US7538252B2 (en) 2006-09-05 2009-05-26 Bipar Sciences, Inc. Drug design for tubulin inhibitors, compositions, and methods of treatment thereof
US7935697B2 (en) 2006-12-28 2011-05-03 Kinex Pharmaceuticals, Llc Compositions for modulating a kinase cascade and methods of use thereof
TWI457336B (zh) 2006-12-28 2014-10-21 Kinex Pharmaceuticals Llc 調節激酶級聯之組成物及方法
US7939529B2 (en) 2007-05-17 2011-05-10 Kinex Pharmaceuticals, Llc Process for the preparation of compositions for modulating a kinase cascade and methods of use thereof
CA2686267C (en) 2007-05-17 2015-10-06 Kinex Pharmaceuticals, Llc Process for the preparation of compositions for modulating a kinase cascade and methods of use thereof
EP2143421A1 (en) 2008-07-07 2010-01-13 Almirall Hermal GmbH Topical composition for the treatment of actinic keratosis
DK2378876T3 (en) * 2008-12-19 2019-03-11 Medicis Pharmaceutical Corp IMIQUIMOD FORMULATIONS WITH LOWER DOSAGE STRENGTH AND SHORT-TERM DOSAGE PLAN FOR TREATMENT OF ACTINIC KERATOSIS
US8741857B1 (en) 2012-01-30 2014-06-03 Lawrence Moy Treatments for actinic keratoses
NZ606177A (en) 2012-01-30 2014-03-28 Dolorgiet Gmbh & Co Kg Compositions for the treatment of actinic keratosis
MX367055B (es) 2012-06-26 2019-08-02 Del Mar Pharmaceuticals El uso de una composición que comprende dianhidrogalactitol, diacetildianhidrogalactitol, y dibromodulcitol, y análogos o derivados de cada uno para el tratamiento de malignidades resistentes a inhibidores de tirosina cinasa.
TWI841523B (zh) * 2017-03-10 2024-05-11 美商Ａｔｎｘ特殊目的實體公司 治療及／或預防光化性角化症之方法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
KINEX PHARMACEUTICALS,, KINEX PHARMACEUTICALS ANNOUNCES ALLOWANCE OF THE INVESTIGATIONAL NEW DRUG (IND) APPLICATION FOR KX2-391 OINTMENT BY THE UNITED STATES FOOD AND DRUG ADMINISTRATION (FDA), 24 July 2014 (2014-07-24) *
KINEX PHARMACEUTICALS,, KINEX RECEIVES FDA APPROVAL TO BEGIN PHASE I STUDY OF KX2-391 OINTMENT FOR ACTINIC KERATOSIS, 25 July 2014 (2014-07-25) *

Also Published As

Publication number Publication date
EP4659740A2 (en) 2025-12-10
JP2020510042A (ja) 2020-04-02
EP3592355B1 (en) 2025-12-10
TW201842913A (zh) 2018-12-16
US20180256589A1 (en) 2018-09-13
AU2018231144A1 (en) 2019-10-03
KR20190141661A (ko) 2019-12-24
ZA202100106B (en) 2022-08-31
EP3592355A1 (en) 2020-01-15
KR20240090837A (ko) 2024-06-21
IL269182B1 (en) 2023-07-01
WO2018165647A1 (en) 2018-09-13
US11497750B2 (en) 2022-11-15
JP2025029010A (ja) 2025-03-05
JP7502863B2 (ja) 2024-06-19
AU2024201828A1 (en) 2024-05-02
BR112019018687A2 (pt) 2020-04-07
US20230172942A1 (en) 2023-06-08
MX2021013354A (es) 2021-11-18
US20200197405A1 (en) 2020-06-25
CN110891575A (zh) 2020-03-17
JP2023015269A (ja) 2023-01-31
TWI841523B (zh) 2024-05-11
CA3055938A1 (en) 2018-09-13
RU2019131757A (ru) 2021-04-12
IL269182A (en) 2019-11-28
AU2018231144B2 (en) 2023-12-21
MX387658B (es) 2025-03-18
US10617693B2 (en) 2020-04-14
RU2019131757A3 (enExample) 2021-05-31
MX2019010707A (es) 2020-01-15
EP3592355A4 (en) 2021-01-06

Similar Documents

Publication Publication Date Title
Sharma et al. Rosacea management: A comprehensive review
US20230172942A1 (en) Methods of treating and/or preventing actinic keratosis
Lynch et al. Management of cutaneous viral warts
KR20140012651A (ko) 파라벤 조성물
Chen et al. Limitations of ALA-PDT as a reliable therapy for AK in clinical practice
US9713608B2 (en) Method for topically treating actinic keratosis on the trunk (except chest) or extremities with ingenol 3-(3,5-diethylisoxazole-4-carboxylate)
Pires et al. Laser-assisted MAL-PDT associated with acoustic pressure wave ultrasound with short incubation time for field cancerization treatment: A left-right comparison
US9492682B2 (en) Combination therapy with low dosage strength imiquimod and photodynamic therapy to treat actinic keratosis
RU2805929C2 (ru) Способы лечения и/или предотвращения актинического кератоза
BR122025000862A2 (pt) Usos do composto kx-01 no tratamento e/ou prevenção da ceratose actínica
NZ727233B2 (en) Stabilized oxymetazoline formulations and their uses
US20170258769A1 (en) A Method for Topically Treating Actinic Keratosis on the Trunk (except chest) and Extremities with Ingenol 3-(3,5-diethylisoxazole-4-carboxylate)
US20170258770A1 (en) Method for Topically Treating Actinic Keratosis on the Full Face or 250 cm2 on the Chest with Ingenol 3-(3,5-diethylisoxazole-4-carboxylate)
US20170258756A1 (en) A Method for Topically Treating Actinic Keratosis on the Scalp with Ingenol 3-(3,5-diethylisoxazole-4-carboxylate)
HK1236391A1 (en) Stabilized oxymetazoline formulations and their uses
HK1236391B (en) Stabilized oxymetazoline formulations and their uses